Tm4sf19 inhibition alleviates imiquimod-induced psoriatic dermatitis by regulating inflammatory signaling pathways and keratinocyte proliferation in mice
Authors:
- 17 April 2026
- journal article
- Published by Springer Nature in Inflammation Research
- Vol. 75 (1)
Abstract
Psoriasis is a chronic inflammatory disease characterized by keratinocyte hyperproliferation, immune cell infiltration, and persistent inflammatory signaling. Although Tm4sf19 has been implicated in inflammatory processes, its contribution to psoriasis pathogenesis remains unclear. We investigate the role of Tm4sf19 in psoriatic inflammation was examined using an imiquimod-induced psoriasis mouse model and HaCaT keratinocytes, in which Tm4sf19 expression was deleted genetically or suppressed pharmacologically with the competitive inhibitor, LEL-Fc. Gene expression, protein expression, and tissue changes were assessed by qPCR, western blotting and histological scoring, respectively. Tm4sf19 expression was significantly elevated in psoriatic lesion. Tm4sf19 knockout or inhibition using LEL-Fc suppressed psoriatic symptoms, macrophage-mediated inflammation and inflammatory cytokine expression. Tm4sf19 inhibition also suppressed the activation of STAT3, EGFR, ERK and KRT17 signaling pathways in keratinocytes. Furthermore, LEL-Fc treatment effectively inhibited LPS-induced cell cycle progression and promoted apoptosis in keratinocyte both in vivo and in vitro. These findings suggest that Tm4sf19 regulates psoriatic inflammation and keratinocyte proliferation through major signaling pathways. Therefore, inhibiting Tm4sf19 may have therapeutic potential for the treatment of psoriasis.Keywords
This publication has 43 references indexed in Scilit:
- Tm4sf19 deficiency inhibits osteoclast multinucleation and prevents bone lossMetabolism, 2023
- New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision MedicineJournal of Investigative Dermatology, 2021
- PsoriasisThe Lancet, 2021
- Therapeutics targeting the IL-23 and IL-17 pathway in psoriasisThe Lancet, 2021
- Pathophysiology, Clinical Presentation, and Treatment of PsoriasisJAMA, 2020
- Keratin 17 as a therapeutic target for the treatment of psoriasisJournal of Dermatological Science, 2012
- IL-17A Upregulates Keratin 17 Expression in Keratinocytes through STAT1- and STAT3-Dependent MechanismsJournal of Investigative Dermatology, 2011
- Tetraspanin-enriched microdomains: a functional unit in cell plasma membranesTrends in Cell Biology, 2009
- PsoriasisThe Lancet, 2003
- The ins and outs of the transmembrane 4 superfamilyImmunology Today, 1994